Showing results (131-140 of 147) with videos related to

Sort By:
Pageof 15
Seminars in Hematology|May 17, 2025
Report of Consensus Panel 6 from the 12th International Workshop on Waldenström's Macroglobulinemia on Diagnosis and Management of Transformed Waldenström's MacroglobulinemiaEric Durot, Jithma P Abeykoon, Damien Roos-Weil, et al.
Hemasphere|November 13, 2024
Prognostic risk and survival of asymptomatic IgM monoclonal gammopathy: Results from a Spanish Multicenter RegistryDavid F Moreno, Cristina Jiménez, Fernando Escalante, et al.
Cancers|April 30, 2021
Defining an Ultra-Low Risk Group in Asymptomatic IgM Monoclonal GammopathyDavid F Moreno, Arturo Pereira, Natalia Tovar, et al.
Frontiers in Immunology|July 16, 2025
Genomic and immune profiling of prognostic risk groups in IgM gammopathy reveals novel biomarkers beyond MYD88 L265PDavid F Moreno, Ferran Nadeu, Fara Brasó-Maristany, et al.
British Journal of Haematology|October 9, 2022
Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemiaDavid F Moreno, Mónica López-Guerra, Sara Paz, et al.
Seminars in Hematology|May 17, 2025
Report of Consensus Panel 4 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with non-IgM lymphoplasmacytic lymphomaAlessandra Tedeschi, Rebecca Auer, Francesco Autore, et al.
Journal for Immunotherapy of Cancer|March 3, 2026
Enhanced antitumoral activity of the academic CAR-T ARI0002h against normal and low BCMA-expressing myeloma cells after incorporating a transmembrane CD28 domainOriol Cardus, Joan Mañé Pujol, Anna de Daniel, et al.
Oncoimmunology|July 13, 2025
TIGIT blockade in the context of BCMA-CART cell therapy does not augment efficacy in a multiple myeloma mouse modelAina Oliver-Caldes, Joan Mañe Pujol, Anthony M Battram, et al.
Leukemia & Lymphoma|March 27, 2020
Impact of intensifying primary antibiotic prophylaxis in at-home autologous stem cell transplantation program for lymphoma patientsLuis Gerardo Rodríguez-Lobato, Alexandra Martínez-Roca, David F Moreno, et al.
Geroscience|December 2, 2023
Astaxanthin and meclizine extend lifespan in UM-HET3 male mice; fisetin, SG1002 (hydrogen sulfide donor), dimethyl fumarate, mycophenolic acid, and 4-phenylbutyrate do not significantly affect lifespan in either sex at the doses and schedules usedDavid E Harrison, Randy Strong, Peter Reifsnyder, et al.
Pageof 15